semaglutide removed from shortage list FDA removes drug FDA's Removal of Semaglutide and
Description
Retrieved 4 October 2025
Retatrutide is described as a triple agonist because the active ingredient targets three receptor systems: GLP-1, GIP, and glucagon
These medications are not intended for casual or cosmetic weight loss, they are designed for people whose excess weight poses a risk to their health
Management of non-GLP-1 health conditions or emergency medical needs
GLP-1 users should avoid meals and snacks that are deep fried, high in sugar or saturated fat and spicy or acidic, since those foods can worsen side effects and work against weight-loss efforts, Snashall said
The challenge, however, has been for people to adopt these in Australia and one of the greatest barriers is perceived cost
